Silence Therapeutics Reports Significant Revenue Decline and Increased Net Losses for Q3 2025

Silence Therapeutics plc reported its financial results for the third quarter and the nine months ended September 30, 2025, revealing a significant decline in revenue and an increase in net losses compared to the previous fiscal period. The company generated revenue of $159,000 for the three months ended September 30, 2025, a decrease of approximately 89% from $1.5 million in the same period of 2024. For the nine months, revenue fell to $525,000 from $18 million, primarily due to a lack of milestone payments from its collaboration with AstraZeneca, which had contributed $10 million in the prior year. The net loss for the quarter was $20.96 million, compared to a loss of $35.54 million in the same quarter of 2024, while the nine-month loss increased to $76.84 million from $57.61 million.

The company's total assets decreased to $146.79 million as of September 30, 2025, down from $202.64 million at the end of 2024. This decline was attributed to reduced cash and cash equivalents, which fell to $82.03 million from $121.33 million, alongside a decrease in other current assets. The accumulated deficit also increased to $550.8 million, reflecting ongoing operational losses. Silence Therapeutics reported a gross profit of $95,000 for the third quarter, a notable improvement from a gross loss of $2.14 million in the same period last year, indicating a reduction in cost of sales.

Operationally, Silence Therapeutics has made strides in its clinical development pipeline, particularly with its siRNA product candidates. The company announced the completion of patient enrollment in the Phase 2 clinical trial for divesiran, aimed at treating polycythemia vera, with initial topline results expected in the third quarter of 2026. The company continues to focus on advancing its proprietary mRNAi GOLD platform and has retained exclusive rights for three targets previously under collaboration with Hansoh, which concluded in December 2024. The company’s workforce has also been streamlined, resulting in restructuring charges of $1.32 million in the previous quarter.

Looking ahead, Silence Therapeutics anticipates continued operational losses as it invests in research and development activities. The company has indicated that its current cash reserves are sufficient to fund operations into 2028, including expected milestone payments from collaboration agreements. However, it will need to secure additional funding to support ongoing clinical trials and operational expenses. The company remains focused on maximizing its collaborations, particularly with AstraZeneca, which could yield significant milestone payments and royalties in the future.